FDA approval for 3 new diagnostic kits
Expected: Q4 FY26 (Apr-Jun 2026)HIGH confidence+₹15 Cr revenue
Expected by April 2026, expanding US market access
Impact: +₹15 Cr revenue
“Management guidance in Q3 earnings call”
3B Blackbio DX Ltd: Is It a Deep Value Opportunity?
Strong
As of Mar 28, 2026, 3B Blackbio DX Ltd (Diagnostics) has a deep value score of 65/100 (rated Strong). 1Y return vs Nifty 500: -28%.
PE: Near PeakStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
🌐FII stake decreased 0.6% this quarter
Re-Rating Catalysts
1. FDA approval for 3 new diagnostic kits
Q4 FY26 (Apr-Jun 2026)HIGH
2. European IVDR certification for 5 kits
Q1 FY27 (Jul-Sep 2026)MEDIUM
Value Trap Risks
1. Coris integration failure
HIGH2. Chinese competition intensifying
MEDIUMKey Numbers
PAT Growth YoY
+69%
Inflection Up
Revenue YoY
+100%
Inflection Up
Operating Margin
43.0%
-1600 bps YoY
PE Ratio
17.4
PEG Ratio
0.00
Current Price
₹1,168
Dividend Yield
0.34%
3Y PAT CAGR
+14%
Market Cap
1.0K Cr
Valuation
Slightly UndervaluedIs 3B Blackbio DX Ltd a Turnaround Opportunity?
Deep value thesis based on recent earnings • Updated Feb 28, 2026
Strategic pivot to molecular diagnostics through acquisition has transformed business model with 98% revenue growth and 45%+ margins, creating a high-growth healthcare play trading at reasonable multiples.
Verdict
TURNAROUND_IN_PROGRESS
What Could Re-Rate 3B Blackbio DX Ltd?
Re-rating catalysts over the next 2-4 quarters • Updated Feb 28, 2026
European IVDR certification for 5 kits
Expected: Q1 FY27 (Jul-Sep 2026)MEDIUM confidence+₹25 Cr revenue
Enables CE marking for new products in EU market
Impact: +₹25 Cr revenue
“Product pipeline disclosed in annual report”
What Are the Value Trap Risks for 3B Blackbio DX Ltd?
Risks that could prevent re-rating or deepen the value trap
Coris integration failure
HIGHMissed synergies or cultural clashes
Impact: -500 bps margin impact
Management view: Management confident in integration timeline with dedicated team assigned
Monitor: Cross-selling metrics in next 2 quarters
Chinese competition intensifying
MEDIUMFurther price wars in diagnostic kits
Impact: -300 bps margin impact
Management view: Focusing on differentiated products and regulatory barriers
Monitor: Market share data in emerging markets
What Is 3B Blackbio DX Ltd's Management Guidance?
Forward-looking targets from management for FY26
Revenue Growth Target
12.5%
Implied PAT Growth
15%
OPM Guidance
44%
Capex Plan
₹10 Cr
Credit Growth Target
20%
Management Tone: CAUTIOUS
Key Milestones
• FDA approvals by Q4
• IVDR certifications by Q1 FY27
How Fast Is 3B Blackbio DX Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +100% | +6% | Inflection Up |
| PAT (Net Profit) | +69% | +14% | Inflection Up |
| OPM | 43.0% | -1600 bps | Volatile |
The above analysis is AI-generated from publicly available financial data. This is educational research only — not investment advice. Last updated Feb 28, 2026.
Frequently Asked Questions: 3B Blackbio DX Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is 3B Blackbio DX Ltd's deep value score?
3B Blackbio DX Ltd has a deep value score of 65/100 (rated Strong). This score is calculated from three components
- Earnings Score: 21/40 — measures PAT growth momentum across quarters
- Underperformance Score: 17/35 — how much the stock trails Nifty 500 (deeper underperformance = higher contrarian signal)
- Quality Score: 12/25 — operational quality (margins, revenue growth, valuation)
Is 3B Blackbio DX Ltd fundamentally improving?
3B Blackbio DX Ltd's quarterly profit (PAT) growth trajectory
- Latest Quarter PAT Growth (QoQ): +49%
- Previous Quarter PAT Growth (QoQ): +19%
- 2 Quarters Ago PAT Growth (QoQ): +57%
- PAT Acceleration: -4.0pp (profits are decelerating)
- 3 consecutive quarters of positive PAT growth
Why is 3B Blackbio DX Ltd underperforming despite good earnings?
3B Blackbio DX Ltd is underperforming the market despite improving earnings — this is the core deep value thesis
- 1-Year Return vs Nifty 500: -28%
- 6-Month Return vs Nifty 500: -7%
- 3-Month Return vs Nifty 500: -5%
- Yet average quarterly PAT growth is +42% — earnings are improving
- The market often takes time to re-rate stocks with improving fundamentals. This gap between price performance and earnings improvement is what deep value research seeks to identify.
What is the earnings momentum for 3B Blackbio DX Ltd?
3B Blackbio DX Ltd's earnings momentum is Decelerating — growth rate is slowing.
- PAT QoQ progression: +57% → +19% → +49% (2Q ago → 1Q ago → latest)
- Acceleration: -4.0pp
- PAT YoY Growth: +69%
Is 3B Blackbio DX Ltd undervalued?
3B Blackbio DX Ltd's valuation metrics
- Price-to-Earnings (PE): 17.2x
- Price-to-Book (PB): 3.4x
- PEG Ratio: 0.0x
- Margin of Safety: +17% (appears undervalued)
What are the revenue and margin trends for 3B Blackbio DX Ltd?
3B Blackbio DX Ltd's revenue and margin trends
- Latest Quarter Revenue Growth (QoQ): +49%
- Average Quarterly Revenue Growth: +33%
- Revenue Acceleration: +24.9pp
- Latest OPM Change: -0.3pp (margins contracting)
- Average OPM Change: +2.6pp
- Revenue YoY: +100%
What is 3B Blackbio DX Ltd's trailing twelve month (TTM) performance?
3B Blackbio DX Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹58 Cr
- TTM PAT Growth: +20.8% YoY
- TTM Revenue: ₹128 Cr
- TTM Revenue Growth: +33.3% YoY
- TTM Operating Margin: 43.3%
What sector does 3B Blackbio DX Ltd belong to?
3B Blackbio DX Ltd key facts
- Sector: Diagnostics
- Market Cap: ₹1.0K Cr
- Rank in Diagnostics: #1 by value score
- Overall rank among all deep value stocks: #71
Is 3B Blackbio DX Ltd a good deep value opportunity to study?
3B Blackbio DX Ltd shows moderate deep value signals — rated Strong with some positive indicators.
- Value Score: 65/100 (Strong)
- Earnings: Not accelerating
- 1Y Underperformance: -28% vs Nifty 500
What is the bull and bear case for 3B Blackbio DX Ltd?
Research Signals (Bull Case)
- 3 consecutive quarters of positive PAT growth
- Appears undervalued based on fair value analysis
- Revenue growth also accelerating
- Operating margins expanding
Risk Factors (Bear Case)
- Earnings growth decelerating
- Margin pressure warning
How does the Diagnostics sector look for deep value?
Diagnostics deep value sector overview
- 1 deep value stocks in this sector
- Average value score: 65/100
- Avg PAT acceleration: -4.0pp
- Top pick: 3B Blackbio DX Ltd
What is deep value investing?
Deep value investing studies stocks that are underperforming the market despite showing improving fundamentals. The thesis is that the market has not yet recognized the earnings recovery, creating a potential valuation gap. It requires patience — recovery can take several quarters.
How is the deep value score calculated?
The deep value score (0-100) combines three factors:
- Earnings (0-40 pts): PAT growth across last 3 quarters, acceleration, and consecutive growth - Underperformance (0-35 pts): How much the stock trails Nifty 500 over 1Y, 6M, 3M (deeper underperformance = higher score) - Quality (0-25 pts): Revenue growth, margin trends, and valuation metrics (PEG, P/B)
Higher score indicates a stronger contrarian research signal.
What are the growth catalysts for 3B Blackbio DX Ltd?
3B Blackbio DX Ltd has 2 key growth catalysts identified from recent earnings analysis
- FDA approval for 3 new diagnostic kits
- European IVDR certification for 5 kits
What are the key risks in 3B Blackbio DX Ltd?
3B Blackbio DX Ltd has 2 key risks worth monitoring
- Coris integration failure
- Chinese competition intensifying
The above FAQs are generated from publicly available earnings data. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.